These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30706636)

  • 1. Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.
    Pastorino F; Brignole C; Di Paolo D; Perri P; Curnis F; Corti A; Ponzoni M
    Small; 2019 Mar; 15(10):e1804591. PubMed ID: 30706636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposome-mediated therapy of neuroblastoma.
    Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
    Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.
    Cossu I; Bottoni G; Loi M; Emionite L; Bartolini A; Di Paolo D; Brignole C; Piaggio F; Perri P; Sacchi A; Curnis F; Gagliani MC; Bruno S; Marini C; Gori A; Longhi R; Murgia D; Sementa AR; Cilli M; Tacchetti C; Corti A; Sambuceti G; Marchiò S; Ponzoni M; Pastorino F
    Biomaterials; 2015 Nov; 68():89-99. PubMed ID: 26276694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
    J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
    Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
    J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles.
    Ponzoni M; Curnis F; Brignole C; Bruno S; Guarnieri D; Sitia L; Marotta R; Sacchi A; Bauckneht M; Buschiazzo A; Rossi A; Di Paolo D; Perri P; Gori A; Sementa AR; Emionite L; Cilli M; Tamma R; Ribatti D; Pompa PP; Marini C; Sambuceti G; Corti A; Pastorino F
    Small; 2018 Nov; 14(45):e1802886. PubMed ID: 30294852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-targeted liposomal therapies of neuroblastoma.
    Pastorino F; Marimpietri D; Brignole C; Di Paolo D; Pagnan G; Daga A; Piccardi F; Cilli M; Allen TM; Ponzoni M
    Curr Med Chem; 2007; 14(29):3070-8. PubMed ID: 18220743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.
    Loi M; Di Paolo D; Soster M; Brignole C; Bartolini A; Emionite L; Sun J; Becherini P; Curnis F; Petretto A; Sani M; Gori A; Milanese M; Gambini C; Longhi R; Cilli M; Allen TM; Bussolino F; Arap W; Pasqualini R; Corti A; Ponzoni M; Marchiò S; Pastorino F
    J Control Release; 2013 Sep; 170(2):233-41. PubMed ID: 23714122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
    Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
    Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
    Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
    Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy.
    Brignole C; Bensa V; Fonseca NA; Del Zotto G; Bruno S; Cruz AF; Malaguti F; Carlini B; Morandi F; Calarco E; Perri P; Moura V; Emionite L; Cilli M; De Leonardis F; Tondo A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Moreira JN; Pastorino F
    J Exp Clin Cancer Res; 2021 Jun; 40(1):180. PubMed ID: 34078433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
    Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide.
    Lin C; Zhang X; Chen H; Bian Z; Zhang G; Riaz MK; Tyagi D; Lin G; Zhang Y; Wang J; Lu A; Yang Z
    Drug Deliv; 2018 Nov; 25(1):256-266. PubMed ID: 29334814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment.
    Di Paolo D; Pastorino F; Brignole C; Marimpietri D; Loi M; Ponzoni M; Pagnan G
    Tumori; 2008; 94(2):246-53. PubMed ID: 18564613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-viral nitric oxide-based gene therapy improves perfusion and liposomal doxorubicin sonopermeation in neuroblastoma models.
    Bellary A; Nowak C; Iwanicki I; Flores-Guzman F; Wu L; Kandel JJ; Laetsch TW; Bleris L; Hernandez SL; Sirsi SR
    Theranostics; 2023; 13(10):3402-3418. PubMed ID: 37351172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
    Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
    Wang Z; Yu Y; Dai W; Lu J; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2012 Nov; 33(33):8451-60. PubMed ID: 22940213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.